Peritoneal Dialysis Daily Versus Six Days Per Week

NCT06399848 | Withdrawn

• 1 other identifier: 75365
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study will enroll patients receiving daily peritoneal dialysis who have significant residual native kidney function. The investiators will visit the patients at a routinely scheduled clinic visit and again at a non-routine visit after the patients skip a single day of dialysis. Blood samples will be obtained and a quality of life questionnaire will be administered at both visits. The primary aim will be to determine whether the patients would prefer daily treatment or being allowed to skip one day per week. Other aims will be to determine the effect of skipping a day on plasma levels of urea nitrogen and creatinine.

Conditions

Peritoneal Dialysis

Outcome Measures

Primary Outcomes (1)

• Patient's preference for treatment regimen

  Patient's stated preference for dialysis daily versus six days per week

  Two weeks per patient

Secondary Outcomes (2)

• Symptoms

  Two weeks per patient

• Plasma solute levels

  Two weeks per patient

Study Arms (1)

Peritoneal Dialysis Daily

OTHER

Each patient will compare their regular daily treatment with the effect of skipping a single day of treatment. There will be no other intervention.

Other: Skip one day of peritoneal dialysis treatment

Interventions

Skip one day of peritoneal dialysis treatment OTHER

Skip one day of peritoneal dialysis treatment

Peritoneal Dialysis Daily

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Daily treament with peritoneal dialysis and residual native kidney funciton with residual urea clearance greater than 2 ml/min.

You may not qualify if:

• less than 3 months on peritoneal dialysis
• recent change in the dialysis prescriptoin
• recent peritonitis

Sponsors & Collaborators

• Stanford University: lead

MeSH Terms

Interventions

SPHKAP protein, human

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 28, 2024
• First Posted: May 6, 2024
• Study Start: July 1, 2024
• Primary Completion: June 1, 2025
• Study Completion: June 1, 2025
• Last Updated: May 22, 2025

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share